US to buy at least 100,000 doses of Lilly's Covid-19 antibody therapy

Lilly's remedy helped reduce the danger of hospitalization and demise in Covid-19 sufferers by 70%, in response to early late-stage trial information put out in January.

Posted by Kunal Gaurav | Reuters

PUBLISHED ON FEB 26, 2021 07:05 PM IST

Drugmaker Eli Lilly and Co stated on Friday the US authorities has agreed to purchase a minimum of 100,000 doses of its newly licensed Covid-19 twin antibody cocktail for $210 million, with doses to be delivered by March-end.

The US authorities could have the choice to buy as much as a further 1.1 million doses by Nov. 25, the corporate stated.

Lilly stated it will start delivery these doses instantly.

The remedy comprises two antibodies bamlanivimab and etesevimab and had bought US emergency use authorization earlier this month.

Like rival Regeneron Prescribed drugs Inc's twin antibody remedy REGN-COV2, Lilly's combo has been licensed for the remedy of delicate to average Covid-19 in sufferers who're at excessive danger of progressing to extreme illness or hospitalization.

Regardless of the federal government's efforts to encourage use of the remedies to assist maintain individuals out of hospitals, the therapies have seen weak demand.

Healthcare programs have stated they've been gradual to ramp up use of the antibodies resulting from further ranges of complexity throughout the pandemic, together with necessities for fast analysis occasions and the necessity to isolate infectious sufferers.

United States had already agreed to purchase 1.45 million doses of bamlanivimab alone, Lilly stated, including that 1 million of doses have already been delivered and 450,000 extra doses can be delivered by March-end.

Background and Overview

Understanding the context behind US to buy at least 100,000 doses of Lilly's Covid-19 antibody therapy helps provide a complete picture of why it has attracted public attention. Over recent months, interest has grown steadily as more details and discussions emerged across various media channels. Keeping up with verified facts ensures readers get an authentic and balanced perspective on the topic.

Key Highlights and Essential Details

Several notable points stand out when looking at the developments surrounding this topic:

Core Details: The primary factors driving interest and why audiences continue to follow updates closely.
Verified Insights: Cross-checked information that clarifies common questions and separates facts from rumors.
Audience Impact: How followers, fans, and observers have responded to the latest announcements and appearances.

Final Thoughts and What to Expect Next

As new developments continue to unfold, staying informed through reliable reporting remains essential. We will continue to follow any upcoming updates, official statements, and noteworthy news related to US to buy at least 100,000 doses of Lilly's Covid-19 antibody therapy. Check back regularly for the latest verified information.